| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310
Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of biomarkers in AD
Progress with trial enrollment following DSMB recommendation to proceed to second dose level
CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer's Disease (AD) and its proprietary Discovery Platform, EpiSelectTM, at the Alzheimer's Association International Conference 2025 (AAIC) taking place in Toronto, Canada from July 27-31, 2025.
Posted In: PMN
